Latest news with #RogueFunds
Yahoo
07-07-2025
- Business
- Yahoo
Here are Rogue Funds' Comments on Costco (COST)
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund depreciated 12.4% net of fees in the quarter. The firm anticipates significant volatility in the near future. Because of the Fund's concentration, significant declines as well as significant rises in the total returns throughout the course of the year are not unusual. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first quarter 2025 investor letter, Rogue Funds highlighted stocks such as Costco Wholesale Corporation (NASDAQ:COST). Costco Wholesale Corporation (NASDAQ:COST) operates membership-based warehouses that offer a range of merchandise categories. The one-month return of Costco Wholesale Corporation (NASDAQ:COST) was -2.75%, and its shares gained 11.44% of their value over the last 52 weeks. On July 03, 2025, Costco Wholesale Corporation (NASDAQ:COST) stock closed at $987.02 per share, with a market capitalization of $437.72 billion. Rogue Funds stated the following regarding Costco Wholesale Corporation (NASDAQ:COST) in its first quarter 2025 investor letter: "Costco Wholesale Corporation (NASDAQ:COST): I believe with the tariffs that Costco stock has barely been impacted but they are extremely vulnerable to recessionary scenarios and aren't as defensive as individuals believe. First, their consumer base is no longer as purely upper middle class as it used to be and will be more exposed to the cyclical nature of retail. Their 'sell in-bulk' nature makes this exposure much worse. Unlike Walmart, if I just got laid off, I don't need to go buy 50 rolls of toilet paper and this makes them much less defensive than Walmart and much more cyclical for low-income consumers (which has slowly made up more and more of their consumer base due to a very slow increase in annual fees). They are currently trading at 55x+ earnings, and I don't usually like to short cult stocks but with expected growth of 11% (I am highly skeptical of this number as they have only grown in the single digits since 2022) and an economic contraction on the horizon, it seems extremely likely to me that they will not be able to hold this valuation for much longer. If we take into account Canada boycotting American goods (Costco's second largest footprint outside of the US, having over 100+ stores) and probably ~8%-10% of goods coming from China along with a 10% tariff on 30% of goods, it is unlikely this bodes well for Costco over the next 9 months. Combining that with a lofty valuation (and no Charlie Munger to tout their horn), we could see a serious pull back. This is set up as a hedge for the portfolio and we will be fine if these expire worthless." A customer in a warehouse aisles, browsing the wide range of branded and private-label products. Costco Wholesale Corporation (NASDAQ:COST) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 93 hedge fund portfolios held Costco Wholesale Corporation (NASDAQ:COST) at the end of the first quarter, which was 96 in the previous quarter. While we acknowledge the potential of Costco Wholesale Corporation (NASDAQ:COST) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Costco Wholesale Corporation (NASDAQ:COST) and shared the list of set-it-and-forget-it stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of COST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-07-2025
- Business
- Yahoo
Should You Hold Achieve Life Sciences (ACHV)?
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund depreciated 12.4% net of fees in the quarter. The firm anticipates significant volatility in the near future. Because of the Fund's concentration, significant declines as well as significant rises in the total returns throughout the course of the year are not unusual. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first quarter 2025 investor letter, Rogue Funds highlighted stocks such as Achieve Life Sciences, Inc. (NASDAQ:ACHV). Achieve Life Sciences, Inc. (NASDAQ:ACHV) is a clinical-stage pharmaceutical company. The one-month return of Achieve Life Sciences, Inc. (NASDAQ:ACHV) was -43.08%, and its shares lost 51.98% of their value over the last 52 weeks. On July 3, 2025, Achieve Life Sciences, Inc. (NASDAQ:ACHV) stock closed at $2.18 per share, with a market capitalization of $108.314 million. Rogue Funds stated the following regarding Achieve Life Sciences, Inc. (NASDAQ:ACHV) in its first quarter 2025 investor letter: "Achieve Life Sciences, Inc. (NASDAQ:ACHV) (Stock and Calls): You can read more about this investment on the Rogue Funds blog here. The company released their first long term trial results in early January and showed zero safety concerns. Despite this being one of the more confident positions for us, it has been an extremely frustrating ride for the Fund and has caused a severe drag in performance that I am not proud of. The current valuation is frankly ludicrous. They delayed NDA filing to June and right after the NDA they will get the July results back, which I expect to be great. They will most likely have to push for a raise to get to PDUFA (likely Q2 of 2026 unless the FDA speeds up approval timelines). In the meantime, after the NDA I still expect a rise in the stock price as they are extremely undervalued to their market potential. After the July study results, if they turn out to be good, it will be very hard to see why they would not be an obvious take-out target. Even with a raise, I still expect the company to have 5x-8x upside from where they are today." A scientist in a lab coat discussing clinical trial results in a laboratory. Achieve Life Sciences, Inc. (NASDAQ:ACHV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 9 hedge fund portfolios held Achieve Life Sciences, Inc. (NASDAQ:ACHV) at the end of the first quarter, compared to 9 in the fourth quarter. While we acknowledge the potential of Achieve Life Sciences, Inc. (NASDAQ:ACHV) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Achieve Life Sciences, Inc. (NASDAQ:ACHV) and shared Rogue Funds' views on the company in the previous quarter in the previous quarter. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of ACHV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-07-2025
- Business
- Yahoo
Rogue Funds' New Holding: Biotricity (BTCY)
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund depreciated 12.4% net of fees in the quarter. The firm anticipates significant volatility in the near future. Because of the Fund's concentration, significant declines as well as significant rises in the total returns throughout the course of the year are not unusual. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first quarter 2025 investor letter, Rogue Funds highlighted stocks such as Biotricity, Inc. (OTC:BTCY). Biotricity, Inc. (OTC:BTCY) is a medical technology company. The one-month return of Biotricity, Inc. (OTC:BTCY) was -19.98%, and its shares lost 45.13% of their value over the last 52 weeks. On July 3, 2025, Biotricity, Inc. (OTC:BTCY) stock closed at $0.42 per share, with a market capitalization of $10.465 million. Rogue Funds stated the following regarding Biotricity, Inc. (OTC:BTCY) in its first quarter 2025 investor letter: "Biotricity, Inc. (OTC:BTCY): This isn't a particularly new holding for the company, but it has been one that we have slowly built a position in since August/September. The company manufactures and sells a three-lead heart monitor and supplies technology that helps in predictability of heart related issues. It can be worn for 30 days and they maintain a 99% retention rate. The device is the best in its class, and they have grown at a solid 25%+ clip to $13mm in revenue that is likely to increase in the near future. In the fall of 2023/early 2024 they began switching their company to focus on providing AI benefits for their device and allowing for a TAAS/SAAS conversion which slowed down sales initially but has led to a large amount of pilot studies taking place. This SAAS conversion has allowed the gross margin to expand significantly, which I expect to continue through the year. A medical professional wearing a lab coat using an advanced ECG device. Biotricity, Inc. (OTC:BTCY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the potential of Biotricity, Inc. (OTC:BTCY) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of BTCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
07-07-2025
- Business
- Yahoo
Here's Why ASP Isotopes (ASPI) Shares Re-rated Positively in Q1
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund depreciated 12.4% net of fees in the quarter. The firm anticipates significant volatility in the near future. Because of the Fund's concentration, significant declines as well as significant rises in the total returns throughout the course of the year are not unusual. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first quarter 2025 investor letter, Rogue Funds highlighted stocks such as ASP Isotopes Inc. (NASDAQ:ASPI). ASP Isotopes Inc. (NASDAQ:ASPI) is a development-stage advanced materials company specializing in the production, distribution, marketing, and sale of isotopes. The one-month return of ASP Isotopes Inc. (NASDAQ:ASPI) was -25.43%, and its shares gained 125.89% of their value over the last 52 weeks. On July 3, 2025, ASP Isotopes Inc. (NASDAQ:ASPI) stock closed at $6.98 per share, with a market capitalization of $585.45 million. Rogue Funds stated the following regarding ASP Isotopes Inc. (NASDAQ:ASPI) in its first quarter 2025 investor letter: "ASP Isotopes Inc. (NASDAQ:ASPI) has begun full production for all three of their plants and the stock price has re-rated positively in response. I believe that Silicon-28 will be sold in the coming weeks, and that Ytterbium will be sold at the end of Q2 or beginning of Q3. This will drive real revenue into the company and will also most likely lead to a serious catalyst in the stock price. I expect a TerraPower deal at any moment, and I believe it is highly likely before Q2 ends. The realization of revenue this quarter combined with a TerraPower deal will most likely have extreme upwards pressure on the stock price, which has a short interest of 35%. A chemist examining a beaker of colored liquid and advanced pharmaceuticals. ASP Isotopes Inc. (NASDAQ:ASPI) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 11 hedge fund portfolios held ASP Isotopes Inc. (NASDAQ:ASPI) at the end of the first quarter, compared to 13 in the fourth quarter. While we acknowledge the potential of ASP Isotopes Inc. (NASDAQ:ASPI) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered ASP Isotopes Inc. (NASDAQ:ASPI) and shared Rogue Funds' views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of ASPI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
17-02-2025
- Business
- Yahoo
Here's Why Rogue Funds Sold RADCOM Ltd. (RDCM)
Rogue Funds, an investment management company, released its fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned 8.59% net of fees in the quarter. This quarter, the Fund's volatility has increased significantly, and the firm anticipates that it will continue to do so. In addition, you can check the fund's top 5 holdings to determine its best picks for 2024. In its fourth quarter 2024 investor letter, Rogue Funds emphasized stocks such as RADCOM Ltd. (NASDAQ:RDCM). RADCOM Ltd. (NASDAQ:RDCM) offers 5G ready cloud-native, network intelligence, and service assurance solutions. The one-month return of RADCOM Ltd. (NASDAQ:RDCM) was -4.16%, and its shares gained 32.38% of their value over the last 52 weeks. On February 14, 2025, RADCOM Ltd. (NASDAQ:RDCM) stock closed at $13.49 per share with a market capitalization of $211.28 million. Rogue Funds stated the following regarding RADCOM Ltd. (NASDAQ:RDCM) in its Q4 2024 investor letter: "RADCOM Ltd. (NASDAQ:RDCM) risk factors include a new CEO risk and a pile of cash that I believe will be spent on an acquisition (or acquisitions) leading to an increase in execution risk. These in combination will decide the fate of the company in the future. I believe that RADCOM could be an interesting opportunity to go forward but despite this, we mainly sold for the opportunity cost of new positions. This position was essentially flat when we sold it and there was no upside or downside to selling when we did. This is a position we might take on again in the future depending on the performance of the CEO and the new acquisition/s. They continue to snatch large contracts but none of that matters much until they get rid of their pile of cash. Their valuation is still very friendly in my eyes." A professional technician using specialized tools to maintain a modern 5G cell tower. RADCOM Ltd. (NASDAQ:RDCM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 7 hedge fund portfolios held RADCOM Ltd. (NASDAQ:RDCM) at the end of the third quarter which was 5 in the previous quarter. While we acknowledge the potential of RADCOM Ltd. (NASDAQ:RDCM) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article we discussed RADCOM Ltd. (NASDAQ:RDCM) and shared the list of latest AI news and ratings on investors' radar. Despite a change in leadership, Rogue Funds expressed its positive outlook on RADCOM Ltd. (NASDAQ:RDCM) in the previous quarter investor letter. In addition, please check out our hedge fund investor letters Q3 2024 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
